Faron Pharmaceuticals Oy
OTC: FPHAF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Markku Tapani Jalkanen
- Employees
- 40
- Headquarters
- Turku, Finland
- IPO year
- 2020
- Market cap
- $209.5M
- Website
- https://www.faron.com
Loading FPHAF…
Loading profile data…Frequently asked questions about FPHAF
What does Faron Pharmaceuticals Oy (FPHAF) do?
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical firm dedicated to drug discovery and development. The company is advancing a pipeline of proprietary drug candidates that harness immune modulation to address significant unmet medical needs, spanning immuno-oncology, organ protection, and regenerative medicine. Its principal product...
Where does FPHAF trade?
Faron Pharmaceuticals Oy (FPHAF) trades on the Other OTC.
What sector is FPHAF in?
Faron Pharmaceuticals Oy (FPHAF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Faron Pharmaceuticals Oy?
Markku Tapani Jalkanen is the chief executive officer of Faron Pharmaceuticals Oy (FPHAF).
Where is Faron Pharmaceuticals Oy headquartered?
Faron Pharmaceuticals Oy is headquartered in Finland.
Does FPHAF pay a dividend?
Faron Pharmaceuticals Oy (FPHAF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FPHAF go public?
Faron Pharmaceuticals Oy (FPHAF) completed its initial public offering in 2020.